



**PharmAust**  
L I M I T E D

# CANINE TRIAL UPDATE

21ST APRIL 2023

**ASX: PAA**

ACN 094 006 023





# HIGHLIGHTS

- Phase 2 trial continues in canines with B-cell lymphoma in Australia, New Zealand and USA
- Two dogs have had a partial response (>30% decrease in cancer tumour) and eight others have enjoyed a stable disease response
- One patient surpasses 280 days with stable disease and continued excellent Quality of Life (QoL), as attested by dog owner testimonials
- MPL/Prednisone extends survival three-fold, to a median of 150 days, while maintaining QoL
- Assay results from 10 x plasma samples expected by late May 2023
- MPL Phase 2 Trial expected to be completed by mid-2023
- PharmAust's commercial strategy aimed at bridging the options of standard-of-care with chemotherapy is on target
- PharmAust in confidential discussions with potential licensing partners for canine cancer



# RECRUITMENT ACTIVITY UPDATE

## Two recent recruits

- Staffordshire Bull Terrier - Perth Veterinary Services
- Shitzu - Western Australian Veterinary Emergency and Specialty (WAVES)

## Additional Specialist Oncology expertise added to sites

- Dr Raelene Wouda (pictured) BVSc(Hons) DACVIM (Oncology) MANZCVS (Small Animal Medicine) BA(Hons)
- Recently joined VSS (Veterinary Specialist Services) Brisbane

## Confirming new US sites

- Additional study site in Austin, TX (Thrive)
- Additional study site in Dallas, TX (Thrive) which has an experienced clinical study co-ordinator on site
- Recruitment at new US sites expected to commence in May

## New Australian sites actively being pursued



# ANALYTICAL UPDATE

- 10 x Plasma samples being collected from sites: ARH Brisbane (005-007, 005-008, 005-010, 005-011), PetFocus Vetcare (002-007, 002-005), Heart of Texas (009-001, 009-002), ARH Homebush (002-006), WAVES (004-008)
- There are no further outstanding plasma samples for assay at any site
- Agilex have set space aside for an early May assay run which provides data in late May

# PET DOG PHASE 2 TRIAL: TREATMENT NAÏVE B CELL LYMPHOMA

CURRENT STATUS OF ENTIRE STUDY ENROLLED DOGS (DAY 28 EVALUATION)

REQUIRE 8 OF A FURTHER 19 DOGS WITH SD AT D28 TO MEET BAYESIAN OUTCOMES FOR SUCCESSFUL PHASE 2 TRIAL

Study metric	# Dogs	#Dogs SD (Stable Disease)		#Dogs PD (Progressive Disease)	#Dogs (Plasma analysis)	#Dogs (On study)
		#Dogs PR (Partial Response)	#Dogs SD (Stable Disease)			
Fully completed	27	2	8	17		
Partially completed*	6				6	
On study**	1					1
<b>Total # dogs</b>	<b>34</b>	<b>10</b>		<b>17</b>	<b>6</b>	<b>1</b>

\*6 dogs partially completed and awaiting plasma analysis to confirm RECIST outcome

\*\*1 dog on trial (WA enrolment)

### RECIST DEFINITIONS

PR = > 30% tumour reduction

SD = <30 % tumour reduction and not >20% tumour increase

### Dogs not included

4 dogs removed from the study due to lack of compliance with tablet administration instruction

1 dog removed due to death on Day 4

5 dogs with plasma MPLS < target level (5 uM)

# DOES DAY 28 VCOG RECIST OUTCOME IMPACT OST (OVERALL SURVIVAL TIME)?

Off Study Retrospective Evaluation of MPL/Prednisolone post study treatments

## DAY 28 – VCOG RECIST (PR/SD)

Dog Study #	# Days (Monepantel monotherapy)	#Days (Monepantel/Prednisolone therapy)	#Days (OST- Overall Survival Time)	Day 28 VCOG RECIST
002-002	28	149	<b>177</b>	<b>SD</b>
004-006	106	38	<b>144</b>	<b>SD</b>
004-005	42	35	<b>77</b>	<b>SD</b>
002-004	63	128	<b>191</b>	<b>SD</b>
005-005	71	111	<b>182</b>	<b>SD</b>
008-001	30	8	<b>38</b>	<b>SD</b>
002-005	81	68	<b>149</b>	<b>PR</b>
002-007	63	14	<b>77</b>	<b>SD</b>

## DAY 28 – VCOG RECIST (PD)

Dog Study #	# Days (Monepantel monotherapy)	#Days (Monepantel/Prednisolone therapy)	#Days (OST- Overall Survival Time)	Day 28 VCOG RECIST
005-002	43	107	<b>150</b>	<b>PD</b>
007-002	28	163	<b>191</b>	<b>PD</b>
005-006	32	125	<b>157</b>	<b>PD</b>
008-002	14	14	<b>28</b>	<b>PD</b>
008-003**	>288	NA	<b>&gt;288</b>	<b>PD</b>
005-007	32	155	<b>187</b>	<b>PD</b>
005-008	14	9	<b>23</b>	<b>PD</b>
005-010*	14	>43	<b>&gt;57</b>	<b>PD</b>
005-011*	28	>23	<b>&gt;51</b>	<b>PD</b>



MPL trial participant



# OUTREACH PROGRAM TO ASSIST IN RECRUITMENT

- Utilised custom paid digital media (Facebook, LinkedIn & Twitter) to drive awareness
- Direct mail and emails to all vets within 40km of existing sites in Australia & New Zealand
- Direct emails to all pet groomers & doggie day-care facilities within 40km of existing sites in Australia & New Zealand
- Multiple podcasts, interviews, articles and advertising in numerous veterinary publications
- Dr Aston attended the Animal Health, Nutrition and Technology Innovation Europe held in March 2023 in London

# VETERINARY TRIAL TESTIMONIALS

- PharmAust upgraded the testimonial page on the Company's website
- Read more on the testimonials from owners of dogs in the MPL trials here:
- <https://www.pharmaust.com/veterinary-trial-testimonials/>



Bella from Melbourne




Louie from New Zealand



Chica from Brisbane



Ruby from Brisbane



Ryley from Sydney





# FOLLOW US ON SOCIAL MEDIA!

[LinkedIn](#)



[Twitter](#)



[Facebook](#)





THIS ANNOUNCEMENT IS AUTHORISED BY THE BOARD

ENQUIRIES:

ANUSHA AUBERT, INVESTOR RELATIONS

[INVESTORENQUIRIES@PHARMAUST.COM](mailto:INVESTORENQUIRIES@PHARMAUST.COM)